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In vitro treatment with a pharmacological dose of sim-
vastatin, a potent pro-drug of a 3-hydroxy-3-methylglu-
taryl-coenzyme A reductase inhibitor, stimulates bone
formation. In our study, simvastatin stimulated differ-
entiation of osteoblasts remarkably in a dose-dependent
manner, with minimal effect on proliferation. To iden-
tify the mediators of the anabolic effects of simvastatin
on osteoblasts, we tried to identify and characterize sim-
vastatin-induced proteins by using proteomic analysis.
Calcyclin was significantly up-regulated by more than
10 times, and annexin I was also up-regulated by sim-
vastatin. However, annexin III, vimentin, and tropomy-
osin were down-regulated. Up-regulated calcyclin
mRNA by simvastatin was validated by reverse tran-
scription in mouse calvarial cells. In confocal micro-
scope analysis, green fluorescence protein-calcyclin fu-
sion protein was ubiquitously observed in the of
MC3T3-E1 cells transfected with green fluorescence pro-
tein-calcyclin cDNA containing plasmid and was quickly
concentrated in the nucleus 20 min after simvastatin
treatment. Overexpression of calcyclin cDNA stimulated
both the proliferation and expression of alkaline phos-
phatase mRNA significantly, without exposure to simv-
astatin in MC3T3-E1 cells. However, both the rate of pro-
liferation of the osteoblasts and the expression of alkaline
phosphatase mRNA were suppressed significantly 1 day
after treatment with the calcyclin-specific small interfer-
ence RNA, and furthermore, simvastatin did not over-
come this suppression in the small interference RNA-
pretreated MC3T3-E1 cells. In conclusion, calcyclin is one
of the candidate proteins that plays a role in osteoblasto-
genesis in response to simvastatin, although the precise
functions of calcyclin in osteoblast remain to be verified.
Osteoporosis is a skeletal disorder characterized by compro-
mised bone strength predisposing to an increased fracture risk
(1, 2). The mainstay of therapy for osteoporosis still focuses on
anti-resorptive agents (3). Anti-resorptive agents stabilize the
bone remodeling by reducing the number and/or the activity of
osteoclasts, thereby reducing the risk of fracture without incre-
ments of true bone mass (4). In contrast, anabolic agents such
as parathyroid hormone (PTH),1 statin, and fluoride directly
stimulate bone formation and increase bone mass (5, 6). Re-
cently, the Food and Drug Administration approved PTH(1–34)
as the first bone anabolic agent for severe osteoporosis. How-
ever, there are several undefined questions regarding the cor-
tical porosity and the possibility of tumorigenesis induced by
PTH(1–34). Therefore, the development of new anabolic agents
is certainly mandatory (7–9).
Statin is a potent pro-drug of a hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitor that is known to inhibit the
conversion of hydroxy-3-methylglutaryl-coenzyme A to meva-
lonic acid, needed for hepatic cholesterol biosynthesis (6, 10).
Mevalonic acid is a precursor not only of cholesterol but also of
proteins such as geranylgeranyl pyrophosphate, which is im-
portant in the control of osteoclast-mediated bone resorption
(11, 12). Previous studies have indicated that some lipophilic
statins have a potent stimulatory effect on bone formation by
inducing the expression of the bone morphogenetic protein
(BMP)-2 (6, 10, 13). However, the detailed mechanisms of how
statins promote bone formation have yet to be elucidated. Little
is currently known about the intracellular statin-induced pro-
teins, as well as the mediator proteins specific for the anabolic
function of statins.
Calcyclin (S100A6), a small acidic protein that weighs about
10 kDa, belongs to the S100 calcium-binding protein family
(14). These family members share a common S100 calcium-
binding motif and are involved in several regulatory functions
that include protein phosphorylation, some enzyme activities,
the dynamics of cytoskeletal components, transcription factors,
and Ca2 homeostasis, and also cell proliferation and differen-
tiation (15, 16). An interesting feature of the S100 proteins is
that they are expressed by epithelial cells and fibroblasts in a
cell-specific way (17). Calcyclin is also expressed by osteoblasts
(MC3T3-E1 cells) and up-regulated markedly during osteoblast
differentiation; however, its roles in bone physiology are un-
known (18).
In the present study, we reassessed whether simvastatin
regulates the proliferation and differentiation of osteoblast-like
cells, and we also explored new protein profiles by proteomic
techniques in response to simvastatin. Here, we found that
calcyclin, the calcium-binding protein, is one of the simvasta-
tin-induced proteins up-regulated by more than 10 times. Fur-
thermore, overexpression of calcyclin by transient transfection
stimulated both the proliferation and differentiation of
MC3T3-E1 cells, as well as inhibiting those without simvasta-
tin treatment through suppressing calcyclin by the siRNA. We* This study was supported by Grant 03-PJ10-PG6-GP01-0002 fromthe Korea Health 21 R & D Project, Ministry of Health & Welfare,
Republic of Korea and Brain Korea 21 Project for Medical Science,
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fluorescence protein; EGFP, enhanced GFP; siRNA, small interference
RNA; MALDI-TOF-MS, matrix-assisted laser desorption/ionization-
time of flight mass spectrometry; -MEM, -modification of Eagle’s
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propose that calcyclin could be one of the mediator molecules
inducing the osteogenic functions of simvastatin.
EXPERIMENTAL PROCEDURES
Cell Cultures—Mouse calvariae were dissected aseptically from post-
natal 1-day Institute of Cancer Research (ICR) mouse. Frontal and
parietal bones were cleaned of loose soft connective tissue and sub-
merged in an -modification of Eagle’s medium (-MEM) (Invitrogen).
Calvariae were digested at 37 °C for 10 min with shaking in an enzy-
matic solution containing 0.1% collagenase (Invitrogen) and 0.05% tryp-
sin containing 0.53 mM EDTA (Invitrogen) in -MEM. This procedure
was repeated to yield a total of five digests. The cells were collected by
centrifugation at 1200 rpm for 5 min and were then resuspended in
-MEM containing 10% fetal bovine serum and antibiotics (100 unit/ml
penicillin and 100 mg/ml streptomycin; all from Invitrogen). The cells
were grown to 70–80% confluence over the next 3–4 days at 37 °C in 5%
CO2 with humidification.
MC3T3-E1 cells were grown in -MEM with 10% fetal bovine serum.
After the cells reached confluence, they were cultured in differentiation
medium (-MEM containing 50 g/ml of phosphate ester of ascorbic
acid (Sigma), 10 mM -glycerophosphate (Sigma), and 108 M dexa-
methasone (Sigma) for 5 days and then subjected to transfection.
Cell Proliferation and Differentiation Assay—Primary-cultured cal-
varial cells were cultured in a 96-well plate and stimulated for only 6 h
with 107 M simvastatin in serum-free -MEM. To assess the long term
effects of simvastatin, the cells were cultured for 8 days being treated
with simvastatin every other day for 6 h intermittently. Cell prolifera-
tion assay was performed using Cell Proliferation Reagent WST-1
(Roche Applied Science) following the manufacturer’s instructions. For
the analysis of cell differentiation, total RNA was extracted from the
cultured cells with a commercial RNeasy kit (Qiagen) following the
manufacturer’s instructions. The purity and amount of isolated RNA
were assessed by spectrophotometric measurement at 260 and 280 nm.
Total RNA (5 g) was reverse transcribed to cDNA at 42 °C for 50 min
in a volume of 20 l containing the following reagents: 0.5 mM dNTP
mixture; 10 mM dithiothreitol; 0.5 mg of oligo(dT), 1 buffer (250 mM
Tris, 375 mM KCl, and 15 mM MgCl2, pH 8.3), and 5 units of RNase
H-free avian myeloblastosis virus reverse transcriptase (Promega).
Then the reaction was terminated at 70 °C for 15 min. Aliquots of the
cDNA were diluted from 1:1 to 1:100. RT-PCR analysis were done: 94 °C
for 5 min, 94 °C for 45 s, 60 °C for 45 s, 72 °C for 35 s (repeated for 30
cycles), and 72 °C for 15 min. The following oligonucleotides were used
for RT-PCR amplification: calcyclin (sequences of EcoRI restriction
enzyme site are underlined), forward 5-GAGAATTCCAGTGATCAGT-
CATGG-3, reverse 5-CAGAATTCCAGAGCTTCATTGTAG-3; alka-
line phosphatase (ALP), forward 5-GGGACTGGTACTCGGATAACG-
3, reverse 5 CTGATATGCGATGTCCTTGCA 3; osteocalcin, forward
5-CGGCCCTGAGTCTGACAAA-3, reverse 5-GCCGGAGTCTGTTC-
CTCCTT-3; Type I collagen, forward 5-GAGGCATAAAGGGTCATC-
GTGG-3, reverse 5-CATTAGGCGCAGGAAGGTCAGC-3; and -ac-
tin, forward 5-TTCAACACCCCAGCCATGT-3, reverse 5-TGTGGT-
ACGACCAGAGGCATAC-3.
Two-dimensional Gel Electrophoresis and Gel Staining—Protein
samples of mouse calvarial cells used for two-dimensional gel electro-
phoresis analysis were obtained by single simvastatin stimulation for
6 h, and nonstimulated samples were used as a control. The samples
were homogenized in a double volume of lysis buffer (8 M urea, 4%
CHAPS, 40 mM Tris, and 20 mM dithiothreitol). Then cell lysates were
FIG. 1. The effect of short and long
term exposure of simvastatin on pro-
liferation of mouse calvarial cells. A,
the short term effect of simvastatin on
mouse calvarial cells was determined af-
ter 6 h of treatment. B, to study the long
term effects of simvastatin, mouse calvar-
ial cells were cultured for 8 days with
intermittent simvastatin treatment (6 h/2
days) in various concentrations (109–
106 M. After the incubation periods, the
absorbance was determined by an enzyme-
linked immunosorbent assay reader. The
data represent the means of triplicate deter-
mination. *, p  0.05; **, p  0.01 simvas-
tatin versus control.
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centrifuged at 12,000 rpm for 15 min at 4 °C. The protein concentration
was determined by the Bradford protein assay, and 100 g of proteins
were used for the analysis. Commercial strips with a nonlinear immo-
bilized pH 4–7 gradient (Amersham Biosciences) were used for isoelec-
tric focusing. These strips were wetted with a rehydration buffer con-
taining 8 M urea, 2% CHAPS, 10 mM dithiothreitol, and immobilized pH
gradient buffer, pH 4–7 (Amersham Biosciences) for 12 h at 50 voltage.
Isoelectric focusing was performed in the Multiphore II apparatus (Am-
ersham Biosciences) for a total of 40,000 V-h. In the second dimension,
the proteins were separated by size in a 7.5–17.5% T polyacrylamide
gradient gel. Two slab gels were run using Protean II xi Cell (Bio-Rad)
at a constant current of 20 mA for 14 h. After electrophoresis, the
separated proteins were either silver-stained or Coomassie Brilliant
Blue-stained. For silver staining, the gels were first fixed for 1 h in 40%
ethanol, 5% acetic acid and then washed with 50 ml of double-distilled
water followed by a second fixing in 5% ethanol, 5% acetic acid. The gels
were washed with 50 ml of double-distilled water and incubated with a
solution of 0.02% sodium thiosulfate (Sigma) for 30 min at room tem-
perature. The gels were washed with 2 10 ml of double-distilled water
and incubated for 90 min at 4 °C with 0.1% silver nitrate solution that
was precooled to 4 °C. The gels were rinsed with 50 ml of double-
distilled water, and the proteins were visualized using a developing
solution containing 0.5% formaldehyde, 2% KCO4 until the proteins
were visible. Acetic acid solution (1%) was used to stop the reaction. For
matrix-assisted laser desorption/ionization-time of flight mass spec-
trometry (MALDI-TOF-MS), the gels were stained with Coomassie Blue
G-250 (0.25%) in 50% methanol, acetic acid overnight at room temper-
ature. Coomassie Blue-stained gels were destained with 40% methanol,
12% acetic acid until the background was clear.
Image Analysis Using PDQuest Software and MALDI-TOF-MS—
Qualitative analysis of digitized images was carried out using PDQuest
two-dimensional analysis software (Bio-Rad). The samples were loaded
onto the target plate using the three layers method (19). 0.6 l of matrix
solution (10 mg/ml sinapinic acid in 60% acetonitrile, 40% water, 0.1%
trifluoroacetic acid, prepared fresh every day) were loaded onto the
sample plates and left to dry at room temperature. One l of sample
solution was deposited on the matrix layer and left to dry. The spot was
then covered with 0.6 l of the matrix solution. The mass spectra were
recorded using a Tof-Spec two-dimensional gel electrophoresis MALDI-
TOF instrument (Micromass, Manchester, UK), equipped with a pulsed
nitrogen laser (337 nm; pulse width, 4 ns), and operated in delayed
extraction linear mode, with an acceleration voltage of 22.5 kV.
pcDNA-cacy and pEGFP-cacy Construction and Transfection—Full-
length calcyclin cDNA amplified by RT-PCR as described above was
sequenced and digested with EcoRI restriction enzyme and purified by
agarose gel electrophoresis. The resulting restriction fragment contain-
ing the entire calcyclin coding region was ligated into the vector pcDNA
3.0 (Invitrogen) and pEGFP-N1 (Clontech). MC3T3-E1 cells were main-
tained in -MEM supplemented with 10% fetal bovine serum, 100
mg/ml streptomycin sulfate, 100 units/ml penicillin G, and 250 mg/ml
amphotericin B. MC3T3-E1 cells were transfected with pcDNA-cacy
and pEGFP-cacy construct using LipofectAMINE reagent (Invitrogen).
Briefly, once the MC3T3-E1 cells reached about 60–70% confluence,
they were washed once with -MEM (serum-free; Invitrogen) and a
mixture of 1 g of plasmid in a total volume of 1 ml/well in a 6-well
plate. Transfection was allowed to proceed for 6 h and followed by the
removal of the transfection medium and the addition of 2 ml -MEM
containing 10% fetal bovine serum. The assays were performed the day
after transfection.
Confocal Microscopic Analysis—For the calcyclin translocation as-
say, MC3T3-E1 cells were transfected with pEGFP-cacy plasmid. After
various treatments, 107 M simvastatin, 107 M PTH(1–34) and co-
incubation with both simvastatin and PTH for 20 min, pEGFP-cacy
transfected cells were washed twice with PBS and fixed in 3% formal-
dehyde (in PBS) at room temperature for 20 min and then rinsed
thoroughly with PBS. Confocal microscopic experiment was performed
on a Zeiss LSM-510 laser scanning microscopy by using a Zeiss 100 oil
immersion lens. Fluorescent signals were collected by using Zeiss LSM
software in the line-switching mode with dual excitation (488 nm, 568
nm) and emission (515–540 nm, 590–610 nm) filter sets. For the nu-
clear staining, Hoescht stock solution (final concentration, 0.12 g/ml)
was added and incubated for 15 min at room temperature. After rinsing
the cells with PBS for five times, the confocal images were visualized
with a light source at 340–350 nm.
siRNA Construction—General guidelines for designing siRNA oligo-
nucleotides are available (20) that require avoiding regions of mRNA
FIG. 2. The effect of simvastatin treatment on mRNA expression of osteoblast differentiation markers. A, ALP, type I collagen and
osteocalcin mRNA expressions increased progressively and dose-dependently with simvastatin exposure over 6 h, whereas -actin mRNA
expression was not modified. B–D, the expression of each differentiation marker was investigated by gel electrophoresis and visualized by EtBr
staining. All of the data illustrate the mean values of three different experiments and are normalized to those of -actin. B, the mRNA expression
level of ALP was significantly elevated in a dose-dependent manner. C, the mRNA expression level of type I collagen significantly increased
dose-dependently but not at the 106 M concentration. D, the mRNA expression level of osteocalcin increased significantly dose-dependently. *, p
0.05; **, p  0.01 simvastatin versus control.
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such as 5- and 3-untranslated regions and regions within 75 bases of
a start codon and sequences having a GC content of 70% or 30%. An
appropriate siRNA sequence within the target calcyclin mRNA se-
quence was chosen according to the manufacturer’s software provided
by Ambion (Austin, TX). 5-AAGGAAGGAGCTGAAGGAGTTG-3 and
5-AAACTTCCAGGAGTATGTCGC-3 siRNA oligonucleotides were
synthesized using the siRNA Construction kit (Ambion) following the
manufacturer’s instructions. Effective RNA interference probes and
their effective concentration were determined based on their ability to
inactivate cognate sequences. Calcyclin and the siRNA effect were
monitored quantitatively using gel analysis. MC3T3-E1 cells were
plated onto 6-well plates for RNA preparation and 96-well plates for the
proliferation assay and then incubated for 24 h. The cells were then
transfected with 10 nM siRNA using the LipofectAMINE reagent ac-
cording to the manufacturer’s instructions.
Statistical Analysis—All of the data were expressed as the means
and standard deviation. SPSS 10.0 software (Chicago, IL) was used for
the statistical analysis, and Student’s t test was used for the compari-
son. The relationships were considered statistically significant when
the p value was less than 0.05.
RESULTS
The Effect of Simvastatin on the Proliferation and Differen-
tiation of Osteoblasts—To examine the effect of simvastatin on
both the proliferation and differentiation of osteoblasts, mouse
calvarial cells were stimulated with simvastatin single treat-
ment for 6 h. For the study of the long term effects of simvas-
tatin, mouse calvarial cells were cultured for 8 days with in-
termittent simvastatin treatment (6 h/2 days) in various
concentrations (109–106 M). Simvastatin was treated inter-
mittently because it has been reported that statins exert a
number of effects that include stabilizing cells and inhibiting
cell proliferation (21, 22). Short term treatment of simvastatin
was not particular effective on osteoblastic proliferation (Fig.
1A) and exhibited a tendency to increase slightly for a long
term effect (Fig. 1B). The proliferation was increased dose-de-
pendently during simvastatin exposure periods and reached a
maximum at 106 M (Fig. 1B).
FIG. 3. Two-dimensional gel protein profiles after simvastatin treatment for 6 h in mouse calvarial cells. A, black circles indicate
proteins whose expression was found to be lower or higher in simvastatin-induced culture relative to control. The horizontal axis of the gels is the
isoelectric focusing dimension, which stretches from pH 4 (left panels) to pH 7 (right panels). The vertical axis is the polyacrylamide gel dimension,
which stretches from about 8 kDa (bottom panels) to about 80 kDa (top panels). 1, 4-fold increase; 2, 4-fold decrease; 11, 10-fold increase. B,
expanded images of the each of the proteins indicated by the same numbers in A showing altered expression upon stimulation with simvastatin
for 6 h.
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As shown in Fig. 2, incubation with 107 M simvastatin for
6 h enhanced the expression of ALP, type I collagen and osteo-
calcin to a statistically significant extent, compared with that
in the unstimulated conditions in cultured mouse calvarial
cells. Because this increase was mostly dose-dependent (109–
106 M), the following experiments were performed with stim-
ulation by a final 107 M of simvastatin for 6 h, unless other-
wise indicated. Quiescent mouse osteoblasts expressed a low
level of ALP mRNA, and this mRNA expression was signifi-
cantly enhanced and saturated by 107 M simvastatin treat-
ment by more than 100-fold (Fig. 2B). Similar to the case of
ALP, the increase in type I collagen expression was significant
at a concentration of 107 M and, interestingly, the expression
dropped to the basal level at the concentration of 106 M (Fig.
2C). In the case of osteocalcin, the mRNA expression increased
dose-dependently and reached a maximum level at a concen-
tration of 106 M (30-fold; Fig. 2D).
Induction of Calcyclin Protein after Simvastatin Treatment
in Mouse Calvarial Cells—Fig. 3 shows an example of a silver-
stained two-dimensional gel electrophoresis images aimed at
determining any change after 6 h of treatment with simvasta-
tin, and these images were analyzed by PDQuest software
(described above). Six spots that showed expressional changes
more than four times were obtained selectively from this anal-
ysis and characterized by MALDI-TOF-MS (Table I). Calcyclin
protein, a member of the S100 calcium-binding protein family,
showed a 10-fold increase after 6 h of simvastatin treatment.
Annexin I and an unidentified spot also increased by more than
four times. However, the others, which included tropomyosin,
annexin III, and vimentin, showed a 4-fold decrease.
The Effects of Simvastatin on mRNA Expression of Calcy-
clin—To confirm the effect of simvastatin on the expression of
calcyclin at the mRNA level, RT-PCR was performed with RNA
obtained from mouse calvarial cells that were either untreated
or treated for 6 h with simvastatin. Fig. 4A illustrates the mean
values of three different experiments and shows that calcyclin
mRNA increased progressively with the increasing time of
simvastatin exposure. Calcyclin mRNA induction significantly
increased as quickly as 30 min after the simvastatin addition
and showed a maximal effect after 1 h (about 60% increase),
and thereafter, the calcyclin mRNA expression returned to the
control level by 24 h. Fig. 4B shows an example of RT-PCR
aimed at determining the effective simvastatin concentration
of calcyclin mRNA induction. The expression of calcyclin
reached almost the maximal level at a concentration of 109 M
and maintained this level to the 106 M concentration.
The Distribution of Calcyclin after Simvastatin Treat-
ment—To determine the cellular localization of calcyclin follow-
ing simvastatin stimulation, calcyclin was fused into enhanced
green fluorescence protein (EGFP), and the fusion protein was
transiently expressed in MC3T3-E1 cells. As shown in Fig. 5,
the fluorescence distributions of the calcyclin were expressed
ubiquitously through the unstimulated MC3T3-E1 cells and
realized by confocal laser scanning microscope. Twenty min-
TABLE I
Identities of the selective simvastatin-induced proteins characterized
by MALDI-TOF-MS
Protein pI Molecularmass Expression level
kDa
1 Calcyclin 5.40 10.5 10-fold increase
2 Annexin I 4.71 39.0 4-fold increase
3 Tropomyosin- 5.96 32.7 4-fold decrease
4 Annexin III 5.06 36.5 4-fold decrease
5 Vimentin 53.7 4-fold decrease
6 Unidentified 4-fold increase
FIG. 4. Time-and dose-dependent induction of calcyclin mRNA expression after simvastatin treatment in mouse calvarial cells. A,
the effect of treatment of mouse calvarial cells with simvastatin 107 M for different time intervals was studied by RT-PCR. Calcyclin appeared
as a single band at about 310 bp, and -actin was used as an internal standard. Calcyclin mRNA expression was significantly increased by
simvastatin after 1 h and then continued to increase for 7 h. Thereafter, it returned to the control value at 24 h. B, the effect of treatment of mouse
calvarial cells with simvastatin at various doses was also studied. Calcyclin mRNA expression was saturated even at the lowest 109 M
concentration at 6 h after simvastatin treatment and showed similar values at 108, 107, and 106 M. *, p  0.05, simvastatin versus control.
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utes after stimulation with simvastatin, the cellular EGFP-
cacy was quickly localized to the nucleus. In these experiments,
the nucleus was stained with Hoechst 33258. PTH(1–34) alone
or a co-treatment of PTH(1–34) with simvastatin also revealed
the similar effects on GFP-cacy localization.
The Effects of Transient Transfection of pcDNA-cacy Plasmid
on Proliferation and ALP mRNA Expression—To examine the
in vitro osteogenic effect of calcyclin in terms of proliferation
and differentiation, we transiently transfected pcDNA-cacy in
MC3T3-E1 cells. By comparison, calcyclin overexpressed cells
showed significantly increased proliferation (Fig. 6A). The ex-
pression of ALP mRNA, which is an early osteoblast differen-
tiation marker, increased significantly the day after the trans-
fection, and the effects were normalized to -actin mRNA
expression (Fig. 6B). This might show the osteogenic potential
of calcyclin in osteoblast in vitro. As for the mRNA expression
of osteocalcin and type I collagen, there was no significant
difference after pcDNA-cacy introduction (data not shown).
The Effects of Complementary Double-stranded RNA against
Calcyclin on Proliferation and ALP mRNA Expression in
MC3T3-E1 Cells—To determine whether the increased ALP
mRNA and increased proliferation after pcDNA-cacy introduc-
tion were truly calcyclin-specific, RNA interference was per-
formed. Two 21-mer siRNAs with 19 complementary nucleo-
tides were synthesized, and a more appropriate template
sequence for calcyclin specific-siRNA was 5-AGGAAGGAGCT-
GAAGGAGTTG-3, which was named siCal (see “Experimental
Procedures”). After siCal introduction to MC3T3-E1 cells, the
expression of calcyclin mRNA was suppressed by 90%, and
simvastatin treatment did not alter the reduced calclyclin ex-
pression (Fig. 7). Entry of siCal performed by transient trans-
fection using LipofectAMINE reduced the proliferation level by
20% (Fig. 8A). The ALP mRNA expression level was tested
and showed very similar but more 5drastic results (Fig. 8B).
Interestingly, simvastatin induction could not alter the effects
of siCal in either case (Fig. 8).
DISCUSSION
Recently, many experimental observations revealed that
simvastatins, potent pro-drugs of a hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitor, stimulated bone formation.
When mouse calvariae were incubated with simvastatin,
greater numbers of osteoblasts and a 3050% increase in ad-
jacent bone width was noted (6). Subsequent epidemiological
studies have suggested that treatment with simvastatin for
hyperlipidemia may be associated with increased bone mineral
FIG. 5. Localization of calcyclin by confocal microscope in MC3T3-E1 cells. Representative fluorescence images in MC3T3-E1 cells after
various treatments, 107 M simvastatin and 107 M PTH(1–34), and co-incubation with both simvastatin and PTH for 20 min. For the nuclear staining,
Hoescht stock solution (final concentration, 0.12 g/ml) was added and incubated for 15 min at room temperature. After rinsing the cells with PBS,
confocal images were visualized with a light source at 340–350 nm on a Zeiss LSM-510 laser scanning microscopy by using a Zeiss 100 oil immersion
lens. A, optical image of MC3T3-E1 cells no transgene expressed. B, left, no GFP signal in the absence of pEGFP-cacy plasmid under confocal
microscopy; right, Hoechst staining of the same cells showing the nuclei. C, in the presence of GFP-cacy fusion protein, a clear signal was evidenced
in the cytoplasm, as well as the nuclei of the cells (in green). D, GFP-cacy fusion protein was quickly concentrated to the nucleus as quickly as 20 min
after simvastatin treatment. E and F, a potent anabolic hormone, PTH(1–34), gave a similar effect on calcyclin localization, as well as following
co-treatment with simvastatin. The nuclei were stained in blue.
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density and reduced fracture risk in humans, even though
there are some controversies (23). The effects of simvastatin
have been suggested to be mediated through the induction of
potent bone-forming growth factors, BMPs. NO production
through statin-induced up-regulated endothelial nitric-oxide
synthase also plays some key role in regulating osteoblast
activity and bone formation (24, 25). However, the action mech-
anisms of simvastatin for inducing pleiotropic effects on bone
have not been well documented yet.
In this study, there was little significant difference on the
degree of proliferation in the simvastatin single-treated mouse
calvarial cells, if any, although a slight, dose-dependent in-
crease of the proliferation occurred over time (8 days). How-
ever, simvastatin significantly increased the transcriptional
level of osteoblast differentiation markers (Fig. 2). Following
the induction of simvastatin for 6 h, the mRNA expression of
alkaline phosphatase, type I collagen, and osteocalcin, were
remarkably enhanced, however, with slightly different aspects
in each. In the type I collagen mRNA, the expression level
dropped dramatically to the basal level at the highest simvas-
tatin concentration. In the previous studies, simvastatin and
subsequently other lipophilic statins such as lovastatin, mev-
astatin, and fluvastatin also resulted in a 2–3-fold increase in
new bone formation and osteoblast cell numbers at all stages of
differentiation (6). Meanwhile, other bone growth factors, such
as transforming growth factor and fibroblast growth factors
were found to stimulate osteoblast proliferation but inhibit
osteoblast differentiation (24, 25).
To identify some key molecules with roles in the anabolic
effects of simvastatin, proteomics analysis was performed. In
cultured mouse calvarial cells, calcyclin, annexin I and III,
vimentin, and tropomyosin- were significantly up- or down-
regulated by simvastatin (Fig. 3). Among the proteins induced,
the most strikingly increased protein was calcyclin (S100A6),
which is a 10.5-kDa protein, belonging to the family of calcium-
binding proteins. Calcium-binding proteins are divided into
two groups; the first group is constituted of annexin, and the
second group is constituted of EF hand proteins as calmodulin
(15, 16, 26). Calcyclin (S100A6), which belongs to the second
group, was first identified as a cellular cycle-dependent protein
FIG. 6. The effect of pcDNA-cacy transfection on proliferation and ALP mRNA expression. A, pcDNA-cacy plasmid was introduced into
MC3T3-E1 using LipofectAMINE, and the proliferation level was determined using WST-1 reagent the day after transfection. Proliferation of
MC3T3-E1 cells was significantly increased by pcDNA-cacy introduction. B, RNA was harvested from MC3T3-E1 cells the day after transfection
with vehicle only (pcDNA 3.0) or pcDNA-cacy and then screened by RT-PCR for ALP expression. ALP mRNA expression was significantly increased
by pcDNA-cacy introduction. The data represent the means of triplicate determination. *, p  0.01 pcDNA-cacy versus vehicle.
FIG. 7. Calcyclin mRNA in MC3T3-E1. Results of gel analysis of
RT-PCR. Each bar represents the mean and standards of error for three
separate experiments of calcyclin densitometry values normalized to
-actin. Subscripts (control and siCal-introduced) showed significantly
different values. *, p  0.01. Calcyclin mRNA expression was signifi-
cantly decreased by siCal and was not altered by simvastatin treatment.
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highly induced by growth conditions (26). Furthermore, the
expression of S100 in osteoblastic cells was verified in various
types of osteosarcomas, in which immunohistochemical stain-
ing for S100 was used to analyze the proliferating cells in
osteosarcomas, and the main proliferating cells to be stained
were found to be mature osteoblast-like cells (27, 28). The
existence of the S100 family in osteoblasts were confirmed in
subsequent studies (18, 29).
S100 family members share a common S100 calcium-binding
motif and have several regulatory functions in, not only protein
phosphorylation, some enzyme activities, the dynamics of cy-
toskeletal components, transcription factors, and Ca2 homeo-
stasis but also the cell proliferation and differentiation (15, 16).
S100 protein family has been known to exhibit an inhibitory
role on protein phosphorylation and target intracellular pro-
teins such as vimentin and annexin I and III (30–32). S100A4,
one of the S100 family members expressed by osteoblastic cells,
is a novel negative regulator of matrix mineralization that
most likely acts by modulating the process of osteoblast differ-
entiation (29). Meanwhile, calcyclin, S100A6, interacts with
tropomyosin- at the intracellular level (16). In this study,
tropomyosin-, a type of cytoskeleton, was down-regulated by
simvastatin concurrent with the up-regulation of calcyclin.
However, its precise role in osteoblasts remains unknown.
Therefore, we focused our experimental efforts on calcyclin,
which seemed to be the key protein regulated by simvastatin.
The mRNA expression of calcyclin was rapidly induced by
simvastatin only 30 min following treatment (Fig. 4A), and the
mRNA expression decreased rapidly to the control level 1 day
after simvastatin induction (Fig. 4A). Because the mRNA ex-
pression of calcyclin was very sensitive to even the lowest
dosage (109 M) of simvastatin, the effect of simvastatin seemed
to be a quite strong and effective inducer of the calcyclin (Fig.
4B). Furthermore, simvastatin also exerted translocating effect
on calcyclin quickly after the exposure (Fig. 5). Calcyclin was
localized ubiquitously throughout the cells, including the cyto-
plasmic compartment, in basal conditions, and it was concen-
trated quickly to the nucleus after 20 min of treatment with
simvastatin. Meanwhile, parathyroid hormone, a potent ana-
bolic hormone on bone, also induced the nuclear translocation
of calcyclin in MC3T3E-1 cells. This fact may suggest that
nuclear transferred calcyclin may turn on or off some impor-
tant genes related to the anabolic effects on osteoblasts induced
by either simvastatin or PTH(1–34). Recently, calcyclin was
found to mediate the serum-responsive element activation by
an osteoblastic extracellular cation-sensing mechanism in
MC3T3-E1 cells (33).
To clarify the role of calcyclin on the anabolic effects of
simvastatin on bone, calcyclin was overexpressed in MC3T3-E1
cells without treatment with simvastatin. Interestingly, both
the rate of proliferation and the expression of alkaline phos-
phatase mRNA were elevated significantly 1 day after trans-
fection (Fig. 6). Expression of calcyclin was abolished by up to
almost 90% by treatment with siRNA against calcyclin (Fig. 7),
and both the rate of proliferation and the expression of alkaline
phosphatase mRNA were decreased significantly 1 day after
the transfection with the siRNA (Fig. 8). Interestingly, sim-
vastatin induction had no effect on the proliferation and ALP
mRNA expression in calcyclin-suppressed MC3T3-E1 cells by
siCal. These results provide strong evidence that calcyclin
plays some important roles as a mediator of simvastatin-in-
duced anabolic effects on bone.
The precise mechanism of how calcyclin has a biological
effect on bone physiology and on osteoblast differentiation re-
mains unclear. But, according to a recent report, S100A6 and
other S100 proteins, through their interaction with ubiquitin
ligases, can regulate the ubiquitination of -catenin in vivo and
thus participate in the process of tumor development and pro-
FIG. 8. The effects of siCal on proliferation and ALP mRNA expression in MC3T3-E1 cells. A, siCal had obvious effects in decreasing
the MC3T3-E1 cell proliferation (p  0.01) just 1 day after its introduction. There was no significant cellular proliferation in calcyclin-suppressed
cells treated with 107 M simvastatin for 6 h. *, p  0.05; **, p  0.01 versus control; #, p  0.05 versus simvastatin-treated control. B, in RT-PCR
analysis after siCal introduction, there was a marked decrease in ALP mRNA expression (p  0.01). Simvastatin did not alter the ALP mRNA
expression when treated to a final concentration of 107 M for 6 h, compared with the negative control (this is also siCal introduced). *, p  0.05;
**, p  0.01 versus control; #, p  0.05 versus simvastatin-treated control.
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gression (34). Activation of endogenous -catenin signaling in
the canonical pathway of wnt induces the expression of alka-
line phosphatase and subsequent osteoblast differentiation
and, further, participates in BMP-2-mediated signal transduc-
tion (35, 36). Therefore, we speculate that in simvastatin-me-
diated osteoblast differentiation, calcyclin, elevated by simvas-
tatin treatment, causes defects in the ubiquitination of
-catenin and its degradation and thus can regulate the osteo-
blast differentiation. Another potential explanation might be
that calcyclin plays a role as a messenger for the induction of
BMP-2 or NO synthase by statin. However, to provide clear
evidence to these novel issues, there needs to be further
investigation.
In conclusion, calcyclin (S100A6) was identified as a new
simvastatin-induced protein and revealed to play important
roles in an anabolic effect of simvastatin on bone. Further
clarification of calcyclin function in osteoblast may discover
novel targets for stimulating bone formation.
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